Compare UiPath Inc (PATH) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Thomson Reuters Corp — how do they compare? UiPath Inc trades at $13.59 (market cap $7.26B), while Thomson Reuters Corp trades at $97 (market cap $42.75B). The key difference: Thomson Reuters Corp is far larger — about 5.9× UiPath Inc's market cap, and Thomson Reuters Corp pays a 2.65% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | TRI | |
|---|---|---|
Market Cap | $7.26B | $42.75B |
Sector | Technology | Industrials |
52-Week High | $19.29 | $173.48 |
52-Week Low | $9.38 | $76.55 |
Enterprise Value | $6.05B | $45.37B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) is trading at $14.01, down 7.77% in the last 24 hours amid mixed technical signals and earnings volatility. The stock shows improving fundamentals with revenue growing from $892M in 2022 to $1.43B in 2025, though profitability remains negative with a -$73.69M net income. Recent Q2 2026 earnings beat expectations but guidance concerns triggered a selloff, with technical indicators showing bearish momentum despite oversold RSI conditions.
PATH presents a turnaround opportunity with strong revenue growth and improving margins, but faces execution risks in competitive AI automation. Analyst consensus targets $17.38 (24% upside) despite cautious ratings, with institutional interest growing. Key risks include sustained profitability challenges and AI competition, while positive cash flow trends and strategic positioning in enterprise automation offer long-term potential.
Thomson Reuters (TRI) trades at $98.81, down 6.5% in 24 hours, with a bearish technical signal and support near $97. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Revenue grew 9% organically, with strong performance in Legal, Corporates, and Tax segments. Net income margin is 21.22%, and the P/E ratio is 26.03. Recent news highlights AI expansion with the launch of the proprietary Thomson-1 LLM and a cybersecurity incident affecting its case management system.
Outlook is mixed: robust recurring revenue and AI adoption support growth, but the stock faces near-term pressure from the price drop and cybersecurity risks. Analysts maintain a buy consensus with a $113 price target, implying 14% upside. Key risks include execution on AI initiatives, competitive pressures, and potential fallout from the security breach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
